

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
WO 2005/092295 A1

(51) International Patent Classification<sup>7</sup>: A61K 9/26, [JP/JP]; Takamidai 16-15, Takatsuki City, Osaka 569-1020 (JP). MURAOKA, Shizuko [JP/JP]; Ueda 3-6-20-902, Matsubara City, Osaka 580-0016 (JP).  
9/58, 31/403

(21) International Application Number: PCT/EP2005/003175 (74) Agent: THOMSEN, Peter et al; Novartis AG, Corporate Intellectual Property, CH 4002 Basel (CH).

(22) International Filing Date: 24 March 2005 (24.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: P200400094 26 March 2004 (26.03.2004) SI

(71) Applicant (for all designated States except US): LEK PHARMACEUTICALS D.D. [SI/SI]; Verovskova 57, 1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOGATAJ, Marija [SI/SI]; Stranska pot 8, 1370 Logatec (SI). MRHAR, Ales [SI/SI]; Milana Majcna 35, 1000 Ljubljana (SI). LAVRIC, Anton [SI/SI]; Gasilska 24, 1291 Skofljica (SI). CERNE, Manica [SI/SI]; Matena 1A, 1292 Ig (SI). TIBAUT, Doris [SI/SI]; Povsetova 104, 1000 Ljubljana (SI). STALC, Anton [SI/SI]; Rasiska 5, 1000 Ljubljana (SI). URLEB, Uros [SI/SI]; Periceva 29, 1000 Ljubljana (SI). MATEOVIC, Tatjana [SI/SI]; Malnarjeva 43, 1000 Ljubljana (SI). COF, Greta [SI/SI]; Zbiljska cesta 103, 1215 Medvode (SI). KERK, Janez [SI/SI]; Trebinjska 7, 1000 Ljubljana (SI). DREU, Rok [SI/SI]; Pot ob Homscici 23, 2380 Slovenj Gradec (SI). YONEDA, Fumio

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims and statement

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM COMPRISING N-(2-(2-PHTHALIMIDOETHOXY)-ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK-423)

(57) Abstract: The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and / or animals by using the pharmaceutical dosage forms of the invention are disclosed.

WO 2005/092295 A1